Barbara Dora
GA29145
Aug 28, 2017AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144
Clinical Studies - Aug 28, 2017 - Aug 28, 2021
Automatically Closed
Project leader: Borovicka Jan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
GA29144/Bergamot
Aug 1, 2017A PHASE III, RANDOMIZED, DOUBLEBLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
Clinical Studies - Aug 1, 2017 - Aug 1, 2021
Automatically Closed
Project leader: Borovicka Jan, Brand Stephan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
Amiselimod
Jun 1, 2017A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis
Clinical Studies - Jun 1, 2017 - Sep 27, 2022
Automatically Closed
Members: Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael
Mongersen GED-0301
Dec 1, 2016A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Completed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
PCG-4/UCR
Dec 1, 2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastroresistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in...
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Completed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Abbvie M14-234
Dec 1, 2016A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Clinical Studies - Dec 1, 2016 - Dec 1, 2018
Automatically Closed
Members: Dora Barbara, Knellwolf Christina, Krieger-Grübel Claudia, Sulz Michael
Entyvio PASS Study
Jul 28, 2016Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...
Clinical Studies - Jul 28, 2016 - Jun 28, 2022
Automatically Closed
Project leader: Brand Stephan
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
PCG-2/UCA
Mar 1, 2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis...
Clinical Studies - Mar 1, 2016 - Dec 31, 2017
Aborted
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
GA289103/Gardenia
Jun 28, 2015GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS
Clinical Studies - Jun 28, 2015 - Jun 28, 2020
Automatically Closed
Project leader: Borovicka Jan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Sulz Michael, Semadeni Gian-Marco
Abbvie M14-033
Mar 1, 2015A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis This Phase 3 study design includes a Screening...
Clinical Studies - Mar 1, 2015 - Feb 1, 2018
Automatically Closed
Project leader: Borovicka Jan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
ALERT
Feb 28, 2015VAlidation of an 8-‐item-‐questionnaire predictive for a positive CaLprotectin tEst and Real-‐life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease
Clinical Studies - Feb 28, 2015 - Jan 30, 2017
Completed
Project leader: Borovicka Jan
Members: Dora Barbara, Sulz Michael
AbbVie M14-115
Feb 1, 2015A Multicenter, Randomisierte, Double-Blind Study to Evaluate the Efficacyand Safety of Two Adalimumab Induction Regimens in Subjects with Moderately to Severely Active Crohns Disease and Evidence of Mucosal Ulceration
Clinical Studies - Feb 1, 2015 - Feb 15, 2018
Automatically Closed
Members: Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael, Dora Barbara
GA28950/Hickory
Jan 1, 2015PHASE III, BLINDED, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS
Clinical Studies - Jan 1, 2015 - Dec 31, 2017
Automatically Closed
Project leader: Borovicka Jan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael
GA28951
Jun 28, 2014GA28951: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES
Clinical Studies - Jun 28, 2014 - Jun 28, 2020
Completed
Project leader: Borovicka Jan
Members: Dora Barbara, Frei Remus, Knellwolf Christina, Semadeni Gian-Marco, Sulz Michael